A detailed history of Massmutual Trust CO Fsb transactions in Exelixis, Inc. stock. As of the latest transaction made, Massmutual Trust CO Fsb holds 1,600 shares of EXEL stock, worth $57,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,600
Previous 1,680 4.76%
Holding current value
$57,279
Previous $37,000 10.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 02, 2024

SELL
$21.96 - $27.6 $1,756 - $2,208
-80 Reduced 4.76%
1,600 $41,000
Q2 2024

Jul 02, 2024

BUY
$20.34 - $23.73 $2,156 - $2,515
106 Added 6.73%
1,680 $37,000
Q1 2024

Apr 09, 2024

SELL
$20.17 - $23.93 $847 - $1,005
-42 Reduced 2.6%
1,574 $37,000
Q4 2023

Jan 03, 2024

BUY
$19.25 - $24.13 $327 - $410
17 Added 1.06%
1,616 $38,000
Q3 2023

Oct 03, 2023

BUY
$19.04 - $22.74 $3,027 - $3,615
159 Added 11.04%
1,599 $34,000
Q2 2023

Aug 01, 2023

BUY
$18.17 - $20.48 $17,134 - $19,312
943 Added 189.74%
1,440 $27,000
Q1 2023

Apr 11, 2023

BUY
$16.3 - $19.41 $4,075 - $4,852
250 Added 101.21%
497 $9,000
Q4 2022

Jan 06, 2023

BUY
$14.96 - $17.39 $2,363 - $2,747
158 Added 177.53%
247 $4,000
Q3 2022

Oct 07, 2022

SELL
$15.68 - $22.27 $376 - $534
-24 Reduced 21.24%
89 $1,000
Q1 2022

Apr 08, 2022

BUY
$17.03 - $22.67 $1,362 - $1,813
80 Added 242.42%
113 $3,000
Q4 2021

Feb 09, 2022

BUY
$15.84 - $21.88 $522 - $722
33 New
33 $1,000
Q3 2018

Nov 09, 2018

SELL
$15.87 - $22.4 $4,443 - $6,272
-280 Closed
0 $0
Q2 2018

Aug 20, 2018

BUY
$18.56 - $22.45 $5,196 - $6,286
280 New
280 $6.03 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Massmutual Trust CO Fsb Portfolio

Follow Massmutual Trust CO Fsb and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massmutual Trust CO Fsb, based on Form 13F filings with the SEC.

News

Stay updated on Massmutual Trust CO Fsb with notifications on news.